ArticleOral oncology2025
Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.
Article in Oral oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Improving stratification in HPV-negative head and neck squamous cell carcinoma (HNSCC) using emerging immune-based biomarkers.Translational cancer research · 2026Article
- Tertiary lymphoid structures: prognostic insights and implications for immunotherapy in HPV-negative head and neck cancer.Translational cancer research · 2026Article
- TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome.Frontiers in oncology · 2026Article
- Understanding the Tumor Microenvironment and Therapy Resistance in Head and Neck Squamous Cell Carcinoma.Cells · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor immune microenvironment (TIME) played a crucial role in head and neck squamous cell carcinoma (HNSCC), significantly impacting disease progression and immunotherapy. To address these complexities, we analyzed gene expression profiles of 790 HNSCC tumors by combining data from The Cancer Genome Atlas (TCGA; n = 520) and the Gene Expression Omnibu database (GEO, n = 270). We identified five distinct TIME-based phenotypes, with the E class-characterized by tertiary lymphoid structures (TLS)-showing the highest survival rates and immunotherapy responses. To assess TLS prognostic value, we evaluated two cohorts of human papillomavirus (HPV) infection negative HNSCC: 247 surgical resection patients and 35 immunotherapy-treated patients with postoperative recurrence/metastasis. Additionally, we analyzed the GEO dataset (n = 102) comprising HNSCC patients with metastasis/recurrence who received PD-1/PD-L1 inhibitors, integrating clinical and transcriptomic data. Immune stratification systems integrating TIME composition and immune cell counts revealed that TLS-positive patients exhibited superior survival and enhanced immunotherapy responses in HPV-negative HNSCC. The two immune stratification systems exhibited greater accuracy and predictive power in estimating the overall survival of HPV-negative HNSCC patients compared to the use of TNM staging and tumor pathological stage. These findings provided a framework for establishing TLS-based personalized treatment in HPV-negative HNSCC, potentially enhancing disease surveillance, informing clinical practice, and improving patient prognosis.
Indexed as
Identifiers
40818211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.